NVO · NYSE
Novo Nordisk
Diabetes and obesity leader with semaglutide franchise and combination peptides in late-stage development.
Overview
Pipeline programs
8Active trials
3Upcoming catalysts
2Indications
3AI research summary
Generated on demand from verified profile data.
Pipeline
Clinical trials
Upcoming catalysts
Timeline
Merged approvals, trial milestones, and catalysts. Newest first.
Sep 12, 2026 · Corporate
EASD Annual Meeting
Source ↗Mar 22, 2026 · Corporate
CagriSema Phase 3 topline (REDEFINE) — guidance window
Source ↗Jan 01, 2026 · Trial Milestone
Phase 3 · REDEFINE — CagriSema in obesity — primary completion (active, not recruiting)
ClinicalTrials.gov ↗Mar 08, 2024 · Regulatory
FDA expands Wegovy label to reduce risk of cardiovascular events in adults with obesity or overweight and established CVD.
FDA ↗Jun 04, 2021 · Approval
FDA approves Wegovy (semaglutide 2.4 mg) for chronic weight management.
FDA ↗Mar 01, 2020 · Trial Milestone
Phase 3 · STEP — semaglutide in obesity — primary completion (completed)
ClinicalTrials.gov ↗Sep 20, 2019 · Approval
FDA approves Rybelsus (oral semaglutide) — first oral GLP-1.
FDA ↗Aug 01, 2018 · Trial Milestone
Phase 3 · SUSTAIN — semaglutide long-term outcomes — primary completion (completed)
ClinicalTrials.gov ↗Dec 05, 2017 · Approval
FDA approves Ozempic (semaglutide) injection for type 2 diabetes.
FDA ↗
Verified sources
- [1]Novo Nordisk IR — Novo Nordisk A/Sretrieved 2026-07-15
- [2]SEC EDGAR — U.S. Securities and Exchange Commissionretrieved 2026-07-15
- [3]FDA — U.S. Food & Drug Administrationretrieved 2026-07-15
- [4]ClinicalTrials.gov — U.S. National Library of Medicineretrieved 2026-07-15
SEC filings search: EDGAR ↗